MedTrace Logo

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

NCT05210283 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1017

Last updated 2026-01-12

No results posted yet for this study

Summary

The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.

Conditions

Interventions

DEVICE

MRD

ctDNA MRD test

Sponsors & Collaborators

  • NSABP Foundation Inc

    collaborator NETWORK

  • Exact Sciences Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2027-05-15
Completion
2027-05-15
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05210283 on ClinicalTrials.gov